KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Other Current Assets

Last Annual Value

78.00K

3-Year CAGR

%

5-Year CAGR

-56%

10-Year CAGR

-33%

KT

Kalaris Therapeutics Inc Competitors Analysis of Other Current Assets

KLRS · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
78.00K
N/A-56.8%N/A 
20.81M
2650.7%50.7%56.1%
4.66M
62.2%N/AN/A
4.41M
-29.5%N/AN/A
2.36M
13.9%N/AN/A
4.43M
-1.5%74.8%N/A
5.61M
-3.5%-2.1%N/A
5.64M
-1.6%N/AN/A
6.04M
43.8%45.8%N/A
3.21M
17.7%51.9%N/A
2.74M
72.2%18.0%30.1%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7